stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Book value per share
AbCellera Biologics Inc.'s book value per share at the end of fiscal 2025 was 3.2×, down 9.79% from 3.6× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 2.9×. Over the past ten years it has ranged from 0.0× (fiscal 2018) to 5.2× (fiscal 2020); the current reading is higher than 38% of that period. AbCellera Biologics Inc. ranks 222nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.2× | (9.79%) |
| FY2024 | 3.6× | (9.96%) |
| FY2023 | 4.0× | (7.89%) |
| FY2022 | 4.3× | 16.31% |
| FY2021 | 3.7× | (28.70%) |
| FY2020 | 5.2× | 7,605.91% |
| FY2019 | 0.1× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 2.9× | (5.26%) |
| Mar 2026 | 3.1× | (4.38%) |
| Dec 2025 | 3.2× | 0.35% |
| Sep 2025 | 3.2× | (4.39%) |
| 24 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| TNGX Tango Therapeutics, Inc. compare | 6.8× |
| RLAY Relay Therapeutics, Inc. compare | 4.4× |
| EWTX Edgewise Therapeutics, Inc. compare | 4.2× |
| ABCL AbCellera Biologics Inc. | 2.9× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 0.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement